Navigation Links
NY Presbyterian/Columbia research presented at Digestive Disease Week meeting
Date:5/9/2011

NEW YORK (May 6, 2011) -- Among those presenting at this year's Digestive Disease Week meeting are physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center. The meeting takes place May 7-10, at McCormick Place, Chicago. The following are two notable research studies:

Dr. Benjamin Lebwohl
A gastroenterologist at NewYork-Presbyterian Hospital/Columbia University Medical Center and instructor in clinical medicine at Columbia University College of Physicians and Surgeons

The prevalence of colorectal neoplasia (CRN) among racial and ethnic minorities in the United States has not been extensively studied. Previous reports of greater polyp prevalence among blacks have not incorporated histologic findings, and adenoma prevalence among Hispanics as compared with blacks and whites is unknown. Dr. Lebwohl and his co-authors did a retrospective analysis of asymptomatic individuals ≥50 years undergoing screening colonoscopy at a single site. They found that prevalence of colorectal adenomas was higher in blacks and Hispanics compared with whites, where blacks had a greater risk of multiple adenomas and Hispanics had a greater risk of large adenomas. Once validated, the authors write, these results may support customized screening and surveillance recommendations based on race and ethnicity to improve outcomes related to colorectal cancer incidence and mortality among diverse, underrepresented populations.

"Increased Prevalence of Colorectal Adenomas and Advanced Neoplasia in Asymptomatic Hispanic and Black Patients Compared to White Patients Undergoing Screening Colonoscopy." AGA Topic Forum. S100-C. Saturday, May 7, 8:30 a.m. CT

Dr. Amrita Sethi
A gastroenterologist at NewYork-Presbyterian Hospital/Columbia University Medical Center and assistant professor of clinical medicine at Columbia University College of Physicians and Surgeons

Single Operator Choledochoscopy (SOC) using the SpyGlass Direct Visualization System (Boston Scientific, Natick, MA) is a platform used to assist in the confirmation of diagnosis of biliary lesions. However, there is little data regarding the interobserver agreement of SPY imaging interpretation. There is currently no established scoring criteria for the cholangioscopic diagnosis of intraductal pathology. In a pilot multicenter study to assess the interobserver agreement and variance in interpretation of SOC, Dr. Sethi and her co-authors report that interobserver agreements of the proposed scoring categories of cholangioscopy images range from slight to fair. The average accuracy of determining a final diagnosis by cholangioscopic imaging by experienced users was less than 40 percent. The authors write that lack of agreement on specific features of imaging as well as the final diagnosis suggest that imaging criteria for malignancy need to be established and training should be addressed.

"Interobserver agreement for Single Operaror Choledochoscopy imaging reading: what are we looking at?" AGA Topic Forum. S101. Saturday, May 7, 8:45 a.m. CT


'/>"/>

Contact: Gloria Chin
pr@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. Dietary research offers new explanations and treatments approaches for gastrointestinal disorders
2. Scripps Research scientists show how shifts in temperature prime immune response
3. Americans Walking, Biking a Bit More, Research Shows
4. Keck Futures Initiative awards $1 million for 13 research projects
5. AGA presents cutting-edge research during DDW
6. Wistar researchers: Direct proof of how T cells stay in standby mode
7. CIRM awards Scripps Research Institute scientists $3.5 million
8. Gates Foundation awards Ben-Gurion U. researcher grant for malaria detection using cell phones
9. Researchers discover protein that could help prevent the spread of cancer
10. US must strengthen efforts to restrict chemicals that threaten health, say researchers
11. New online crisis management and evaluation tool introduced by researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... agency serving communities in the greater Dallas, Miami, and Raleigh regions, is organizing ... fighting to overcome a rare and deadly chromosome abnormality. , After struggling since ...
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve ... engagement.” The patient is doing more than filling out a survey; in many cases ... an increasing emphasis in health care and research on the importance of active engagement ...
(Date:10/13/2017)... LEXINGTON, Ky. (PRWEB) , ... October 13, 2017 , ... ... MD, MPH to become its next President and Chief Executive Officer, succeeding Dr. James ... and CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a ... utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the ... a CBD form that can be easily incorporated into liquid products, while reducing costs ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... INDIANAPOLIS , Oct. 2, 2017  Eli Lilly ... its financial results for the third quarter of 2017 ... a conference call on that day with the investment ... performance. The conference call will begin at ... public can access a live webcast of the conference ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: